Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Delafloxacin Powder vs Tablet in Healthy Subjects
NCT06612255Phase 1Terminated
- Sponsor
- Melinta Therapeutics
- Start
- Jun 2024
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of delafloxacin in bacterial pneumonia (4 arms), sponsored by Melinta Therapeutics. Primary endpoint: Area Under the Mean Concentration Time Curve From Time 0 to 24 Hours Post-dose. Started Jun 2024; status: terminated.
02
Drugs
delafloxacin
03
Conditions
bacterial pneumonia
Beyond the preview
Go deeper on NCT06612255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06612255.